MX336947B - Ligandos esteroides y su uso en la modulacion de genes interruptores. - Google Patents

Ligandos esteroides y su uso en la modulacion de genes interruptores.

Info

Publication number
MX336947B
MX336947B MX2013006609A MX2013006609A MX336947B MX 336947 B MX336947 B MX 336947B MX 2013006609 A MX2013006609 A MX 2013006609A MX 2013006609 A MX2013006609 A MX 2013006609A MX 336947 B MX336947 B MX 336947B
Authority
MX
Mexico
Prior art keywords
steroidal ligands
gene switch
switch modulation
nuclear receptor
steroidal
Prior art date
Application number
MX2013006609A
Other languages
English (en)
Inventor
Robert E Hormann
Silvia Lapenna
Laurence Neil Dinan
Original Assignee
Intrexon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp filed Critical Intrexon Corp
Publication of MX336947B publication Critical patent/MX336947B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/723—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
    • C07C49/727—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con ligandos esteroides para uso en sistemas de expresión de genes inducibles basados al receptor nuclear. La invención se relaciona adicionalmente con métodos para modular la expresión de genes de interés con un sistema que contiene uno o más complejos de receptor nuclear y uno o más ligandos esteroides. Los aspectos adicionales incluyen composiciones de ligando que incluyen composiciones terapéuticas.
MX2013006609A 2008-03-14 2009-03-16 Ligandos esteroides y su uso en la modulacion de genes interruptores. MX336947B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3664808P 2008-03-14 2008-03-14
US4705708P 2008-04-22 2008-04-22
US6070608P 2008-06-11 2008-06-11
PCT/US2009/001639 WO2009114201A2 (en) 2008-03-14 2009-03-16 Steroidal ligands and their use in gene switch modulation

Publications (1)

Publication Number Publication Date
MX336947B true MX336947B (es) 2016-02-08

Family

ID=41065739

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010009996A MX2010009996A (es) 2008-03-14 2009-03-16 Ligandos esteroides y su uso en la modulacion de genes interruptores.
MX2013006609A MX336947B (es) 2008-03-14 2009-03-16 Ligandos esteroides y su uso en la modulacion de genes interruptores.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010009996A MX2010009996A (es) 2008-03-14 2009-03-16 Ligandos esteroides y su uso en la modulacion de genes interruptores.

Country Status (12)

Country Link
US (2) US8536354B2 (es)
EP (1) EP2265116A4 (es)
JP (1) JP5777890B2 (es)
KR (1) KR101695035B1 (es)
CN (1) CN102014626B (es)
AU (1) AU2009223721B2 (es)
BR (1) BRPI0908747A2 (es)
CA (1) CA2718494C (es)
IL (1) IL208692A (es)
MX (2) MX2010009996A (es)
RU (1) RU2487134C2 (es)
WO (1) WO2009114201A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0908747A2 (pt) 2008-03-14 2023-04-18 Intrexon Corp Ligantes esteróides e seu uso em modulação de comutador genético
CN102234303B (zh) * 2010-05-07 2013-04-03 重庆植恩药业有限公司 蜕皮甾酮合成衍生物及其制备方法和用途
FR2982489B1 (fr) * 2011-11-10 2013-12-27 Inst Biophytis Sas Phytoecdysones pour leur utilisation dans la stabilisation du poids apres un regime amaigrissant
FR3021318B1 (fr) * 2014-05-20 2017-04-28 Inst Biophytis Produits derives de la 20-hydroxyecdysone et leur utilisation dans la preparation de medicaments
CN104756919B (zh) * 2015-04-20 2017-05-03 福建师范大学 一种诱导龟足金星幼虫附着变态的方法
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
EP3419996A4 (en) 2016-02-24 2019-09-18 Aromyx Corporation BIOSENSOR TO ODOR DETECTION SCENT AND TASTE
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
UY37343A (es) * 2016-07-25 2018-02-28 Intrexon Corp Control del fenotipo en plantas
EP3858365B1 (en) 2016-09-01 2024-01-31 Chimera Bioengineering Inc. Gold optimized car t-cells
IL310711A (en) 2017-01-10 2024-04-01 Intrexon Corp Modulation of expression of polypeptides through a new system for changing gene expression
FR3078252B1 (fr) * 2018-02-28 2020-08-14 Biophytis Phytoecdysones pour leur utilisation dans la prevention de la perte de force musculaire lors d’une immobilisation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
WO1991014695A1 (en) 1990-03-22 1991-10-03 The Salk Institute For Biological Studies Insect retinoid receptor compositions and methods
WO1996027673A1 (en) 1995-03-03 1996-09-12 Novartis Ag Control of gene expression in plants by receptor mediated transactivation in the presence of a chemical ligand
TR200003861T2 (tr) * 1995-05-26 2001-04-20 Zeneca Limited Bir ekdison reseptörünü içeren bir gen anahtarı.
EP0910652B1 (en) 1996-04-05 2014-10-08 The Salk Institute For Biological Studies Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
CA2296093A1 (en) 1997-07-10 1999-01-21 The Salk Institute For Biological Studies Modified lepidopteran receptors and hybrid multifunctional proteins for use in regulation of transgene expression
US6333318B1 (en) * 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6258603B1 (en) 1998-06-17 2001-07-10 Rohm And Haas Company Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
AU3642601A (en) * 1999-11-05 2001-05-30 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
CA2404253C (en) 2000-03-22 2014-05-13 Rohm And Haas Company Novel ecdysone receptor-based inducible gene expression system
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
US8715959B2 (en) 2001-02-20 2014-05-06 Intrexon Corporation Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
JP4955905B2 (ja) 2001-02-20 2012-06-20 イントレキソン コーポレーション キメラレチノイドｘ受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用
US9493540B2 (en) 2001-02-20 2016-11-15 Intrexon Corporation Ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
US9249207B2 (en) 2001-02-20 2016-02-02 Intrexon Corporation Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system
CA2459807C (en) 2001-09-26 2013-09-03 Jianzhong Zhang Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
EP1436394A4 (en) 2001-09-26 2004-12-29 Rheo Gene Holdings Inc CICADA ECDYSON RECEPTOR NUCLEIC ACIDS, POLYPEPTIDES AND THEIR USE
US20050228016A1 (en) 2002-06-13 2005-10-13 Enrique Michelotti Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
US7375093B2 (en) * 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US20040049437A1 (en) 2002-09-11 2004-03-11 Govone Solutions, Lp Method, system and computer program product for automating transaction tax calculation
AU2003284316A1 (en) * 2002-10-24 2004-05-13 Albert Einstein College Of Medicine Of Yeshiva University Caged ligands and uses thereof
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7304162B2 (en) 2003-02-21 2007-12-04 Intrexon Corporation Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
FR2863878B1 (fr) * 2003-12-22 2006-06-30 Oreal Utilisation d'ecdysteroides pour la preparation de compositions dermathologiques ou cosmetiques anti-chute de cheveux.
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US20050191385A1 (en) * 2004-10-25 2005-09-01 Amato Daniel K. Natural product derivatives as food supplements and pharmaceuticals
BRPI0908747A2 (pt) 2008-03-14 2023-04-18 Intrexon Corp Ligantes esteróides e seu uso em modulação de comutador genético

Also Published As

Publication number Publication date
US8536354B2 (en) 2013-09-17
US9243263B2 (en) 2016-01-26
EP2265116A2 (en) 2010-12-29
RU2487134C2 (ru) 2013-07-10
WO2009114201A2 (en) 2009-09-17
CN102014626B (zh) 2016-01-13
BRPI0908747A2 (pt) 2023-04-18
JP2011518121A (ja) 2011-06-23
US20090298175A1 (en) 2009-12-03
IL208692A (en) 2016-10-31
WO2009114201A3 (en) 2009-12-30
MX2010009996A (es) 2010-10-20
KR20100127828A (ko) 2010-12-06
IL208692A0 (en) 2010-12-30
AU2009223721B2 (en) 2015-01-29
CA2718494C (en) 2016-05-17
AU2009223721A1 (en) 2009-09-17
US20140057349A1 (en) 2014-02-27
JP5777890B2 (ja) 2015-09-09
EP2265116A4 (en) 2013-02-06
KR101695035B1 (ko) 2017-01-23
RU2010140194A (ru) 2012-04-20
CA2718494A1 (en) 2009-09-17
CN102014626A (zh) 2011-04-13

Similar Documents

Publication Publication Date Title
MX336947B (es) Ligandos esteroides y su uso en la modulacion de genes interruptores.
PH12018502500A1 (en) Methods and compositions for determining resistance to androgen receptor therapy
PH12018500394A1 (en) Pd-l1 ("programmed death-ligand 1") antibodies
MY171654A (en) Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
IL202377A0 (en) Chiral diachylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
MX2014014951A (es) Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
MX341119B (es) Estructuras multiméricas específicas para ligando inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trail).
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MX343773B (es) Uso de ligandos sigma en dolor por cancer de huesos.
MY191313A (en) Use of chimeric antigen receptor-modified t cells to treat cancer
MX2009006812A (es) Moduladores del receptor c3a y metodos de uso de los mismos.
TN2010000169A1 (en) Molecules and methods for modulating complement component
WO2010042890A3 (en) Polypeptides that bind trail-ri and trail-r2
GB201013767D0 (en) Identification of ligands and their use
MX359210B (es) Composición de combinación de pac-1 y tamoxifeno.
WO2014028941A3 (en) Adipose composition systems and methods
MX2019006527A (es) Moduladores de la actividad del complemento.
MX2015001551A (es) Compuestos y composiciones activadoras de enzima.
IN2015DN04209A (es)
WO2012018616A3 (en) Polypeptides that bind trail-r1 and trail-r2
MX2009011421A (es) Derivados de ftalazina e isoquinolina con actividades moduladoras del receptor de la s1p.
MX2010001187A (es) Moduladores del receptor ccr9 y metodos para su uso.
MX337767B (es) Tecnologia de simulacion integrada.
MX2012002013A (es) Moduladores de activador del factor de crecimiento de hepatocitos.